Catheter reperfusion and intravenous thrombolysis with tissue plasminogen activator (tPA) are often used clinically to reduce tissue damage in patients with cerebral ischemia, but the inability of many patients to seek or obtain this treatment promptly has led to severe brain damage and disability, thus, the current state of stroke treatment is still faced with limitations, and the growing urgency of developing highly effective neuroprotective agents for acute ischemic stroke. The gene discussed is PLAT; the disease is brain ischemia.